Emerging targeted therapies in haematological malignancies - European Medical Journal

Emerging targeted therapies in haematological malignancies

Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE, discusses the recent development of molecularly targeted therapies in the management of haematological malignancies.

Emerging targeted agents include monoclonal antibody (mAb) targeting Signaling Lymphocytic Activation Molecule F7 (SLAMF7), elotuzumab, for multiple myeloma; anti-CD38 mAb, daratumumab, for multiple myeloma; anti-CD20 mAb, obinutuzumab, for chronic lymphocytic leukaemia (CLL); and ibrutinib plus bendamustine for CLL.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now